| Hemophilia A
Afstyla vs Eloctate
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Afstyla vs Eloctate with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEloctate has a higher rate of injection site reactions vs Afstyla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eloctate but not Afstyla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afstyla
Eloctate
At A Glance
IV infusion
2-3 times weekly
Recombinant Factor VIII
IV infusion
Every 3-5 days
Recombinant Factor VIII Fc fusion protein
Indications
- Hemophilia A
- Hemophilia A
Dosing
Hemophilia A - On-demand treatment and control of bleeding Target Factor VIII activity 20-40 IU/dL for minor bleeds, 30-60 IU/dL for moderate bleeds, and 60-100 IU/dL for major/life-threatening bleeds; repeat IV injection every 8-24 hours until bleeding is resolved. Dose (IU) = body weight (kg) x desired Factor VIII rise (IU/dL) x 0.5.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 20-50 IU/kg IV 2-3 times weekly; children may require more frequent dosing based on pharmacokinetic data and individual response.
Hemophilia A - Perioperative management Target 30-60 IU/dL for minor surgery (repeat every 24 hours for >=1 day); target 80-100 IU/dL for major surgery (repeat every 8-24 hours until adequate wound healing, then maintain 30-60 IU/dL for >=7 more days) via IV injection.
Hemophilia A - Routine Prophylaxis 50 IU/kg IV every 4 days; adjust to 25-65 IU/kg at 3-5 day intervals based on patient response.
Hemophilia A - On-demand (Minor/Moderate Bleeding) 20-30 IU/kg IV, repeat every 24-48 hours until the bleeding episode is resolved.
Hemophilia A - On-demand (Major/Life-threatening Bleeding) 40-50 IU/kg IV, repeat every 12-24 hours until bleeding is resolved (approximately 7-10 days).
Hemophilia A - Perioperative (Minor Surgery) 25-40 IU/kg IV, repeat every 24 hours for at least 1 day until healing is achieved.
Hemophilia A - Perioperative (Major Surgery) 40-60 IU/kg IV preoperatively, then 40-50 IU/kg every 8-24 hours, continuing every 24 hours for at least 7 days post-wound healing.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to AFSTYLA or any excipient (e.g., polysorbate 80) or to hamster proteins
- Life-threatening hypersensitivity reaction to ELOCTATE or its excipients (sucrose, sodium chloride, L-histidine, calcium chloride, polysorbate 20)
Adverse Reactions
Most common (>0.5%) Factor VIII inhibition (in previously untreated patients), hypersensitivity, dizziness
Postmarketing Factor VIII inhibitor development
Most common in previously treated patients (>0.5%) Arthralgia, malaise, myalgia, headache, rash
Most common in previously untreated patients (>=1.0%) Factor VIII inhibition, device-related thrombosis, rash papular
Postmarketing Factor VIII inhibitor development, hypersensitivity
Pharmacology
AFSTYLA is a recombinant single-chain Factor VIII with a truncated B-domain and covalent linkage between heavy and light chains that replaces missing Coagulation Factor VIII needed for effective hemostasis; it exhibits higher VWF affinity relative to full-length rFVIII, providing increased molecular stability and protection from degradation.
ELOCTATE is a recombinant fusion protein that temporarily replaces missing Coagulation Factor VIII needed for effective hemostasis; its Fc region of IgG1 binds to the neonatal Fc receptor (FcRn), delaying lysosomal degradation and prolonging plasma half-life compared to standard recombinant Factor VIII.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afstyla
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Eloctate
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Afstyla
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Eloctate
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Afstyla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Eloctate
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfstylaView full Afstyla profile
EloctateView full Eloctate profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.